|
|
Previous Article | Table of Contents | Next Article 
Transplantation of Filgrastim-Mobilized Peripheral Blood Stem Cells From HLA-Identical Sibling or Alternative Family Donors in Patients With Hematologic Malignancies: A Prospective Comparison on Clinical Outcome, Immune Reconstitution, and Hematopoietic Chimerism
Dietrich W. Beelen,
Helmut D. Ottinger,
Ahmet Elmaagacli,
Birgit Scheulen,
Oliver Basu,
Bernhard Kremens,
Werner Havers,
Hans Grosse-Wilde, and
Ulrich W. Schaefer
From the Departments of Bone Marrow Transplantation, Pediatric Hematology and Oncology, and the Institute of Immunology, University Hospital of Essen, Essen, Germany
The clinical results, cellular immune reconstitution, and hematopoietic chimerism obtained after transplantation of recombinant human granulocyte colony-stimulating factor mobilized allogeneic peripheral blood stem cells (PBSCs) from genotypically human leukocyte antigen (HLA)-identical sibling (n = 36) or alternative family donors (n = 24) were prospectively compared in patients with hematologic malignancies. Thirty-two of 34 evaluable patients with HLA-identical sibling donors and all patients with alternative family donors achieved trilineage engraftment. The median time intervals to reach peripheral neutrophil counts <500/µL (13 v 17 days) or <1,000/µL (16 v 19 days) and unsupported platelet counts <20,000/µL (11 v 15 days) or <50,000/µL (19 v 24 days) as well as red blood cell and platelet transfusion requirements were not significantly different between both patient subsets. The cumulative probability of grades II through IV acute graft-versus-host disease (GVHD) for the 60 study patients was 48% ± 10% but ranged between 86% ± 12% in patients whose donors had at least one HLA-A,B,DR,DQ,DP antigen disparity in direction to acute GVHD, and 25% ± 9% in recipients of GVHD-matched transplants (P < .003). The 2-year survival estimates were 54% ± 10% for patients with alternative family donors and 65% ± 9% for patients with HLA-identical sibling donors. Multivariate analysis identified the pretransplantation disease stage, patient age, and acute GVHD as independent predictors of overall and disease-free survival, whereas alternative family donors alone had no adverse effect on these clinical endpoints. Monthly monitoring of peripheral blood T-helper cell subsets, B cells, and monocytes during the first year posttransplantation showed a nearly identical course of immune cell reconstitution in both patient subsets. In addition, no differences in the proportions of complete chimeric patients were detectable between the two patient subsets by sex chromosome and variable number of tandem repeats analysis up to 12 months posttransplantation. In conclusion, PBSCs from alternative family donors represent an attractive source for allogeneic transplantation in patients lacking HLA-identical sibling donors and should be further evaluated in comparison with marrow transplants from alternative family donors.
Blood, Vol. 90 No. 12 (December 15), 1997:
pp. 4725-4735
© 1997 by The American Society of Hematology.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. H. C. Baumeister, K. Holig, M. Bornhauser, M. Meurer, E. P. Rieber, and K. Schakel
G-CSF mobilizes slanDCs (6-sulfo LacNAc+ dendritic cells) with a high proinflammatory capacity
Blood,
October 15, 2007;
110(8):
3078 - 3081.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Takahashi, J. Ooi, A. Tomonari, T. Konuma, N. Tsukada, M. Oiwa-Monna, K. Fukuno, M. Uchiyama, K. Takasugi, T. Iseki, et al.
Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen
Blood,
February 1, 2007;
109(3):
1322 - 1330.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Remberger, D. W. Beelen, A. Fauser, N. Basara, O. Basu, and O. Ringden
Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors
Blood,
January 15, 2005;
105(2):
548 - 551.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. D. Ottinger, S. Ferencik, D. W. Beelen, M. Lindemann, R. Peceny, A. H. Elmaagacli, J. Husing, and H. Grosse-Wilde
Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors
Blood,
August 1, 2003;
102(3):
1131 - 1137.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H. Elmaagacli, S. Basoglu, R. Peceny, R. Trenschel, H. Ottinger, A. Lollert, V. Runde, H. Grosse-Wilde, D. W. Beelen, and U. W. Schaefer
Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia
Blood,
February 15, 2002;
99(4):
1130 - 1135.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Tzachanis, A. Berezovskaya, L. M. Nadler, and V. A. Boussiotis
Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses
Blood,
February 15, 2002;
99(4):
1465 - 1473.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Remberger, O. Ringden, I.-W. Blau, H. Ottinger, B. Kremens, M. G. Kiehl, J. Aschan, D. W. Beelen, N. Basara, G. Kumlien, et al.
No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors
Blood,
September 15, 2001;
98(6):
1739 - 1745.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. E. Champlin, N. Schmitz, M. M. Horowitz, B. Chapuis, R. Chopra, J. J. Cornelissen, R. P. Gale, J. M. Goldman, F. R. Loberiza Jr, B. Hertenstein, et al.
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
Blood,
June 15, 2000;
95(12):
3702 - 3709.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-J. Liu and B. Blom
Introduction: TH2-inducing DC2 for immunotherapy
Blood,
April 15, 2000;
95(8):
2482 - 2483.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Arpinati, C. L. Green, S. Heimfeld, J. E. Heuser, and C. Anasetti
Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
Blood,
April 15, 2000;
95(8):
2484 - 2490.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Przepiorka, T. L. Smith, J. Folloder, I. Khouri, N. T. Ueno, R. Mehra, M. Korbling, Y. O. Huh, S. Giralt, J. Gajewski, et al.
Risk Factors for Acute Graft-Versus-Host Disease After Allogeneic Blood Stem Cell Transplantation
Blood,
August 15, 1999;
94(4):
1465 - 1470.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H. Elmaagacli, D. W. Beelen, B. Opalka, S. Seeber, and U. W. Schaefer
The Risk of Residual Molecular and Cytogenetic Disease in Patients With Philadelphia-Chromosome Positive First Chronic Phase Chronic Myelogenous Leukemia Is Reduced After Transplantation of Allogeneic Peripheral Blood Stem Cells Compared With Bone Marrow
Blood,
July 15, 1999;
94(2):
384 - 389.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Ringden, M. Remberger, V. Runde, M. Bornhauser, I.W. Blau, N. Basara, K. Holig, D.W. Beelen, H. Hagglund, O. Basu, et al.
Peripheral Blood Stem Cell Transplantation From Unrelated Donors: A Comparison With Marrow Transplantation
Blood,
July 15, 1999;
94(2):
455 - 464.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Engelhardt, H. Bertz, M. Afting, C. F. Waller, and J. Finke
High- Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34+ Immunoselection
J. Clin. Oncol.,
July 1, 1999;
17(7):
2160 - 2160.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Neipp, T. Zorina, M. A. Domenick, B. G. Exner, and S. T. Ildstad
Effect of FLT3 Ligand and Granulocyte Colony-Stimulating Factor on Expansion and Mobilization of Facilitating Cells and Hematopoietic Stem Cells in Mice: Kinetics and Repopulating Potential
Blood,
November 1, 1998;
92(9):
3177 - 3188.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|